Antonio Wolff, MD (#HealthPolicyIsEconomicPolicy)

med onc @JHBreastGyn @HopkinsKimmel @HopkinsMedicine, @JohnsHopkins professor, @CLOSLER member. @ASCO fellow. @NCICTEP_ClinRes. @SusanGKomen scholar 🇧🇷/🇺🇲

[Antonio Wolff, MD (#HealthPolicyIsEconomicPolicy) @awolff]

Why #ClinicalTrials? Because they matter. They help us develop the best interventions & treatments, and often ensure patients receive the best possible care. #BCSM #ItTakesAVillage @JHBreastGyn @hopkinskimmel

[Johns Hopkins Kimmel Cancer Center @hopkinskimmel]

October is #breastcancerawarenessmonth. @awolff from @hopkinskimmel explains the benefit of clinical trials to both patients undergoing treatment and those who will be diagnosed in the future. #bcsm

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

Don’t miss Dr. Erica Mayer (@elmayermd) presenting results from a Phase II study on neoadjuvant niraparib with dostarlimab for patients with BRCA- or PALB2-mutated #BreastCancer, focusing on the ER+/HER2- cohort, at the #SABCS24 Rapid Fire 3 session. @TheTBCRC

🗓️ Friday, December 13th
⏰ 12:00 – 12:50 pm CST (1:00 – 1:50 pm EST)
📍 Hall 1

[Tatiana Prowell, MD @tmprowell]

#SABCS24
Dr. @awolff: Must study impact of new #cancer drugs on reproductive health.

⌛️ He believes we are under-utilizing ovarian suppression & over-utilizing chemo in premenopausal w/ #breastcancer, & window to answer this Q definitively in #bcsm #clinicaltrials is closing.

[Translational Breast Cancer Research Consortium @TheTBCRC]

We are grateful for the support of @BCRFcure & @SusanGKomen. See you soon at #SABCS24!

[Gelareh Sadigh, MD @GelarehSadigh]

We are excited to have this trial open for patients with #metastatic #breastcancer treated an NCI community oncology practices #NCORP
@eaonc @awolff @ruthcarlosmd @ilana_graetz @LynneWagnerPhD

[Antonio Wolff, MD (#HealthPolicyIsEconomicPolicy) @awolff]

It was a treat to do the Highlights of the Day I - Breast Ca Metastatic, and contextualize the great work of presenters and discussants. Thou shalt not forget to watch the fantastic talk by discussant @MayoClinic Dr. Ciara O'Sullivan.

[Yara Abdou, MD, MSCR @YAbdouMD]

Taking a moment to acknowledge that many places, especially in third world countries, lack access to essential drugs and resources. We are fortunate to have more in the US.

A shout out to Dr. O’Sullivan for acknowledging that treatment paradigms are not applicable everywhere, we often take that for granted ‼️

#HealthEquity #AccessToCare #ASCO24 #bcsm

@MayoCancerCare @ASCO @OncoAlert

[Sara Tolaney @stolaney1]

RxPONDER: AMH (low levels associated w/ diminished ovarian reserve) in women classified as premenopausal

If low AMH --> no benefit from adj chemo
If med/high AMH--> ⬆️4.4% in 5 yr DRFS w/ chemo

Suggests:chemo impact may be due to impact on ovarian fxn

@OncoAlert #ASCO24

[Translational Breast Cancer Research Consortium @TheTBCRC]

Dr. Nadine Tung discusses TBCRC048 at #ASCO24 - olaparib is effective in patients with MBC with inherited PALB2 mutation or tumor acquired BRCA1 or BRCA2 mutation. Benefit in initial trial confirmed in a larger group of patients @TheTBCRC @OncoAlert

[Antonio Wolff, MD (#HealthPolicyIsEconomicPolicy) @awolff]

@TheTBCRC

[Sara Tolaney @stolaney1]

Wonderful work by Nadine Tung on TBCRC 048

Olaparib in gPALB2 and sBRCAm expansion cohorts for MBC (to validate initial findings)

gPALB2 n=24 (79% ER+). ORR 75%, CBR 83%, PFS 9.6 mo

sBRCA (n=30) ORR 37%, CBR 53%, PFS 7.2 mo

@OncoAlert #ASCO24 #bcsm

[Antonio Wolff, MD (#HealthPolicyIsEconomicPolicy) @awolff]

@TheTBCRC

[Translational Breast Cancer Research Consortium @TheTBCRC]

TBCRC049 presented by PI @barbaraobrienmd demonstrated symptom and quality of life improvement, intracranial response & extended survival with the HER2Climb regimen for patients with leptomeningeal disease from HER2+ bc. #ASCO24 @ASCO

[Antonio Wolff, MD (#HealthPolicyIsEconomicPolicy) @awolff]

So grateful, @TarahBallinger. We are privileged that you chose to bring your brilliance to @eaonc and brighten the work we do to improve care for our patients. @NCICancerCtrl #ASCO24

[Angie DeMichele, MD, MSCE, FASCO @AngieDemichele]

@TarahBallinger @eaonc @awolff @LynneWagnerPhD @YAbdouMD Tarah, your presentation was just fantastic, and your work a true testament to your passion, commitment and skill. I am honored to work with you. Can’t wait to see what you will do next!!

[Antonio Wolff, MD (#HealthPolicyIsEconomicPolicy) @awolff]

#TrialsThatImpactPatientCare Congratulations to the @eaonc EAZ171 Team! #ASCO24 See full press release https://t.co/VNM4tc4oP5 and simultaneous JCO paper https://t.co/Lm8y03RSrM

[ECOG-ACRIN Cancer Research Group @eaonc]

Check out @JCO_ASCO Podcast: "EAZ171: Predictors of TIPN in Black women with #BreastCancer" w/ Dr. @ShannonWestin & Dr. @BryanSchne90417. EAZ171 was presented at the #ASCO24 Annual Meeting.
@TarahBallinger @NCIprevention #NCORP @SusanGKomen @VBFoundation https://t.co/y0tGoIuVVe

[Translational Breast Cancer Research Consortium @TheTBCRC]

ETHAN - groundbreaking new @TheTBCRC trial for male breast cancer led by PI Dr. Pablo Leone. #ASCO24

Learn more at https://t.co/oD1sOu7g2e

[Translational Breast Cancer Research Consortium @TheTBCRC]

In case you missed @GuiNaderMarta @elmayermd poster on TBCRC030! #ASCO24

[Translational Breast Cancer Research Consortium @TheTBCRC]

PI Dr. Tiffany Traina presenting the actively enrolling TBCRC058 trial #ASCO24 @RitaNandaMD

Find more info at: https://t.co/WKuJM2KQ4A

[Translational Breast Cancer Research Consortium @TheTBCRC]

TBCRC058 aims to evaluate treatment in metastatic ER-negative / ER-low AR+ breast cancer. Learn more about the study at #ASCO24 @TheTBCRC

[Michelle DeMeo @MKDeMeo]

Tomorrow #ASCO24 check out @NTungMD present #TBCRC048 olaparib expanded cohorts of gPALB2 and sBRCA MBC, one of the most rewarding studies I’ve managed in the last decade and a testament to the power of investigator-initiated research @BIDMChealth @DFCI_BreastOnc @TheTBCRC

[Michelle DeMeo @MKDeMeo]

TBCRC048 is a collaborative IST led by #DFHCC and was open at 11 academic centers across the US via @TheTBCRC - thank you to the incredibly dedicated study teams at each of the sites and, most importantly, the 114 participants, many of whom traveled great distances for the study

[Translational Breast Cancer Research Consortium @TheTBCRC]

As seen today at #ASCO24 - TBCRC026, HER2-E and tumors with increased immune signaling more likely to respond to HER2-directed therapy in ER-/HER2+ breast cancer treated with neoadjuvant HP without chemo. @TheTBCRC @HennessyMaeve

[Antonio Wolff, MD (#HealthPolicyIsEconomicPolicy) @awolff]

#ASCO24 @TheTBCRC

[Nancy Lin, MD @nlinmd]

TBCRC 049: Tucatinib, trastuzumab, capecitabine for HER2+ LMD
-The first prospective LMD trial to show all of the following:
-therapeutic drug levels in CSF
-intracranial response
-improvement in symptoms and QoL
-extended OS compared to historical controls

[Antonio Wolff, MD (#HealthPolicyIsEconomicPolicy) @awolff]

This is what qualifies for an oncologist to be in the presence of a rock star ⁦⁦@NIHDirector⁩ ! #asco24 ⁦@judywawira⁩ ⁦@RamalingamMD⁩